Neuroscientific Biopharmaceuticals

Neuroscientific to Acquire Leading Stem Cell Technology

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) to acquire StemSmartTM patented Stem Cell technology (StemSmart), for the manufacture of life-changing cellular medicine, Mesenchymal Stromal Cells (MSC), from Isopogen WA Ltd (Isopogen WA).


About StemSmart Acquisition

  • Early indications from the Phase 2 trial in refractory Crohn’s disease suggest StemSmartTM MSC is potent, efficacious and safe (refer to Annexure 1 for a summary of the details and findings from the Phase 2 trial).
  • StemSmart™ MSC is derived from adult human donor bone marrow. The MSCs are isolated and grown in culture, before the patented StemSmart™ manufacturing process is applied to improve the cells’ clinical efficacy.
  • StemSmart™ MSC works by interacting with a patient’s immune system to modulate immune responses.
  • MSCs respond to inflammation by secreting factors that reduce the activation and proliferation of immune cells and down-regulate their production of inflammatory mediators.
  • Patients both locally and interstate have already received StemSmart™ MSC therapy on compassionate grounds, for a variety of serious and life-threatening clinical conditions, with multiple strong positive clinical responses.
  • Special Access Program in fistulising Crohn’s disease to commence immediately following completion of the Acquisition (defined below).

The Growing Importance of Stem Cell Therapy

  • Stem cell therapy is a cornerstone of modern medicine. Stem Cells have the unique ability to develop into different cell types in the body and are often hailed as the body’s master cells.
  • Stem cell therapies are rapidly gaining global recognition as a transformative therapeutic modality.
  • The US FDA recently approved the first mesenchymal stromal cell (MSC) therapy (Mesoblast ASX Announcement 19.12.2024 (ASX: MSB)). This decision paves the way for renewed enthusiasm and global investment in clinical research of MSC therapies.

StemSmart Key Addressable Markets

  • Crohn’s Disease: Global market US$13.8 billion by 20261;
  • Kidney Transplant: Global market for organ transplant immuno-suppressants, increasing to US$7.2 billion by 20302 (majority for renal);
  • Lung Disorders: Global market US$33 billion by 20343; and
  • GvHD: Global market increasing to US$0.640 billion in 20264.

StemSmartTM and Crohn’s Disease

  • The StemSmartTM MSC patented technology’s immediate focus will be to undertake a Special Access Program (“Program”) in fistulising Crohn’s disease. There is a strong need for alternative and effective treatments for Crohn’s Disease, with fewer side effects.
  • Fistulas are one of the most severe and debilitating complications associated with Crohn’s disease.
  • Fistulising Crohn’s disease is challenging to treat, and sustained healing has proven limited with standard therapies. If successful, this Program is intended to progress to a Phase 1/2 clinical trial.
  • Previously, a Phase 2 trial of 18 patients with refractory Crohn’s disease who received StemSmartTM MSC therapy demonstrated promising results, with the majority of patients experiencing clinical improvement and many, clinical remission (refer to Annexure 1 for a summary of the details and findings from the Phase 2 trial).

Acquisition of StemSmart

  • NSB proposing to acquire 100% of the issued capital of Isopogen WA, which holds or has the right to exploit the StemSmartTM patented Stem Cell technology (StemSmart).
  • Binding share sale agreements have already been signed with the Key Sellers of Isopogen WA (defined below), who collectively hold 51.4% of the issued capital of Isopogen WA.

Capital Raising and Proposed Appointments

  • Firm commitments received to raise $3.5 million (before costs) at a share price of $0.035 each via a placement to professional, sophisticated and qualifying investors.
  • Proposed appointments of Robert McKenzie and Paul Fry to the board of directors and Marian Sturm as Chief Scientific Adviser.
  • Post completion cash on hand of approximately A$7.5million.

NeuroScientific founding Director, Dr Anton Uvarov said,“We’re incredibly excited to add mesenchymal stem cell technology to our growing portfolio. This acquisition not only complements our existing pipeline of therapeutic peptides, but also strategically positions us at the forefront of next-generation biologics. Stem cell therapies are rapidly gaining global recognition as a transformative therapeutic modality, especially with recent FDA approvals highlighting their clinical potential. We see this as a powerful opportunity to expand our impact in regenerative medicine and deliver innovative solutions to patients across a range of conditions.”


Click here for the full ASX Release

This article includes content from Neuroscientific Biopharmaceuticals, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less
Amplia Therapeutics

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.
Keep reading...Show less
Nutritional Growth Solutions Limited

Binding Commitments Received for A$1.0 Million under Convertible Note Placement

Nutritional Growth Solutions Limited (ASX:NGS) ("NGS" or "the Company"), is pleased to announce that it has received binding commitments for the issue of 1,000,000 convertible notes (Placement CNs), to be issued at $1.00 each (CN Placement).

Keep reading...Show less

Latest Press Releases

Related News

×